AVAC will be hosting a webinar on Tuesday, May 20 at 10am ET during which representatives of the US Centers for Disease Control (CDC) will discuss the new clinical guidelines on using daily oral TDF/FTC (also known as Truvada) as PrEP for HIV prevention, released by the CDC and the US Public Health Service. This is the first such national guideline issued anywhere for PrEP use. It provides clear instructions for health providers about providing TDF/FTC as PrEP for individuals at "substantial risk for HIV infection". This is a significant step to making this PrEP strategy a well-understood and accessible option for men and women living in the United States. Ideally other countries and global agencies will replicate this important step.
Register for the webinar here.
- Download the Clinical Practice Guidelines
- Download the Clinical Providers' Supplement
- Read the CDC press release
Also, on Tuesday, May 20 at 1pm ET the CDC will host Public Health Grand Rounds on PrEP, which will be live webcast and archived after the event. Click here for details.
For more information on PrEP research, ongoing implementation projects, access, guidance and more, visit www.prepwatch.org.
